Newsletter
Morepen Laboratories jumped 13% after it bagged an order worth ₹825 crore from a leading global pharma player to make medicines for them.
Note: this is one of the company’s largest-ever single CDMO contracts.
Breaking it down: the order covers structured, multi-year supply with end-to-end capabilities from development to commercial manufacturing.
Instead of selling just raw drug ingredients, the company will now handle the full process, from developing the product to manufacturing it at scale. It’s like being hired as a trusted factory partner for a big international drug brand.
Broader perspective: for years, many Indian pharma companies largely operated as API suppliers, meaning they sold bulk drug ingredients to global pharma firms.
That’s a lower-margin, more commoditised business. But this deal pushes Morepen deeper into the CDMO space (Contract Development and Manufacturing Organisation) where companies handle everything from product development to final commercial manufacturing.
Factors behind this: cost is one factor why global players are tapping Indian companies. India offers competitive manufacturing. But it’s no longer just about being cheaper.
Global pharma companies are actively diversifying supply chains away from single-country dependence (especially post-Covid and China+1 strategy).
